Pfizer Quality Improvement Request for Proposals: Improving the Quality and Standardization of Pneumococcal Diagnostic Pathways in Pediatric and Adult Populations
Pfizer Inc. funds projects in Italy to standardize and enhance pneumococcal diagnostic pathways and surveillance for both pediatric and adult populations.
Funder: Pfizer Inc.
Due Dates: October 19, 2026: Submission Deadline
Funding Amounts: Up to EUR 50,000 per project | Total program budget: EUR 300,000 | Project duration: up to 2 years
Summary: Supports quality improvement projects in Italy to standardize and enhance pneumococcal diagnostic pathways and surveillance data.
Key Information: Only Italian hospitals, ASLs, universities, IRCCSs, or accredited private clinics are eligible; individuals or unaffiliated groups are not.
Description
This grant opportunity from Pfizer Inc. aims to advance the quality and standardization of microbiological diagnostic pathways for Streptococcus pneumoniae in both pediatric and adult populations in Italy. The focus is on addressing diagnostic performance gaps by supporting projects that implement evidence-based practices, optimize diagnostic processes, and improve the reliability and completeness of serotype surveillance data. Eligible projects may include the standardization of diagnostic bundles, enhancement of sample management, integration of advanced diagnostics into clinical practice, improvement of data capture and quality assurance, and the development of educational and training activities for diagnostic appropriateness. The initiative encourages collaboration between clinicians and laboratories and the creation of standard operating procedures and clinical workflows to support continuous quality improvement.
